Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Phathom Pharmaceuticals Inc PHAT

Healthcare
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are... see more

Recent & Breaking News (NDAQ:PHAT)

PHAT FRAUD ALERT: Jakubowitz Law is Investigating Phathom Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws

PR Newswire June 2, 2023

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire June 1, 2023

PHAT INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.

PR Newswire June 1, 2023

PHAT NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.

PR Newswire May 31, 2023

PHAT ALERT: The Law Offices of Vincent Wong Investigate Phathom Pharmaceuticals, Inc. for Potential Violations of Securities Laws

PR Newswire May 31, 2023

PHAT FRAUD ALERT: Jakubowitz Law is Investigating Phathom Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws

PR Newswire May 30, 2023

PHAT NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.

PR Newswire May 29, 2023

INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Phathom Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ: PHAT)

PR Newswire May 26, 2023

PHAT INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Phathom Pharmaceuticals, Inc.

PR Newswire May 25, 2023

ROSEN, A TOP RANKED FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - PHAT

Newsfile May 25, 2023

Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock

GlobeNewswire May 23, 2023

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock

GlobeNewswire May 23, 2023

Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA

GlobeNewswire May 23, 2023

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT

PR Newswire May 22, 2023

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT

PR Newswire May 22, 2023

Phathom Pharmaceuticals Reports First Quarter 2023 Results

GlobeNewswire May 10, 2023

Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023

GlobeNewswire May 9, 2023

PHAT INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT

Newsfile April 17, 2023

ROSEN, Global Investor Counsel, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT

Newsfile April 15, 2023

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire April 12, 2023